Sean Laaman

Q: What is Sean Laaman's success rate?

Sean Laaman currently has a success rate of 75.1248987152287.

Q: What is the average return of Sean Laaman's calls?

Their stock ratings have generated an average return of 13.757977402133866.

Morgan Stanley | Healthcare

Sean Laaman is an analyst from Morgan Stanley specializing in the Healthcare sector. Ranked #2297 out of 4773 analysts, they have issued 29 stock ratings with a success rate of 75.12% and an average return of 13.76%.

Sean Laaman has a well-established track record, with 29 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 75.12% and an average return of 13.76%, underscoring their expertise and ability to identify winning opportunities for investors.

#2297

Out of 4773

Total Ratings

+75.12%

Success Rate

+13.76%

Average Return

Recent Ratings Analysis

ARGX

Buy

Aug 18, 2026

Target

$1230.00

Current

$984.04

Performance

-0.90%

Sean Laaman rated ARGX as Overweight on Aug 18, 2026, setting a price target of 1230. Shares have remained stable near 984.04, leaving the 1230 target still in play.

MPLT

Hold

Jul 28, 2026

Target

$21.00

Current

$13.79

Performance

11.98%

On Jul 28, 2026, MPLT was given a Equal-Weight rating by Sean Laaman, with a target price of 21. The stock rallied from 13.785 to 13.785 after the Hold rating, surprising to the upside.

EXEL

Hold

Jul 23, 2026

Target

$53.00

Current

$57.43

Performance

3.20%

EXEL received a Equal-Weight rating from Sean Laaman on Jul 23, 2026, aiming for 53. Shares remained flat at 57.43, aligning with the neutral rating.

ERAS

Hold

Jul 20, 2026

Target

$21.00

Current

$16.03

Performance

-14.82%

On Jul 20, 2026, Sean Laaman published a Equal-Weight outlook on ERAS, with a target of 21. Weakness in the stock, now at 16.03, supported the conservative rating.

IRON

Buy

Jun 16, 2026

Target

$85.00

Current

$74.14

Performance

6.17%

Sean Laaman on Jun 16, 2026 assigned IRON a Overweight rating, with a price target of 85. The Buy call aligned well with market performance, producing a gain of 6.17%.

BBIO

Buy

May 28, 2026

Target

$98.00

Current

$72.50

Performance

5.92%

On May 28, 2026, Sean Laaman reaffirmed BBIO with a Overweight rating, targeting 98. The recommendation was supported by strong follow-through as the stock rose from 72.5 to 72.5.

GENB

Buy

May 14, 2026

Target

$22.00

Current

$15.39

Performance

-0.52%

GENB was rated Overweight by Sean Laaman on May 14, 2026, with a price objective of 22. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

CERT

Hold

May 12, 2026

Target

$10.00

Current

$7.42

Performance

45.78%

On May 12, 2026, Sean Laaman initiated coverage on CERT with a Equal-Weight rating and target of 10. The Hold stance underestimated the stock’s strength as it gained 45.78%.

AXSM

Hold

May 05, 2026

Target

$242.00

Current

$211.12

Performance

-5.36%

Sean Laaman issued a Equal-Weight recommendation for AXSM on May 05, 2026, price target set at 242. Market action validated the conservative Hold outlook with shares at 211.115.

EIKN

Buy

Mar 02, 2026

Target

$32.00

Current

$9.21

Performance

-38.10%

On Mar 02, 2026, EIKN was evaluated by Sean Laaman, who gave a Overweight rating and target of 32. Investors saw limited payoff as shares fell short of the 32 target.

BBOT

Buy

Dec 05, 2025

Target

$20.00

Current

$5.52

Performance

-59.68%

Sean Laaman rated BBOT as Overweight on Dec 05, 2025, setting a price target of 20. The stock has underperformed, dropping 59.68% despite the bullish target of 20.

RMD

Buy

Oct 21, 2025

Target

$304.00

Current

$219.58

Performance

-18.13%

On Oct 21, 2025, RMD was given a Overweight rating by Sean Laaman, with a target price of 304. Despite the Buy call, shares fell from 219.58 to 219.58, challenging the optimistic stance.

ONC

Buy

Oct 20, 2025

Target

$383.00

Current

$341.80

Performance

7.29%

ONC received a Overweight rating from Sean Laaman on Oct 20, 2025, aiming for 383. Momentum has favored the Buy call, with shares climbing from 341.8 to 341.8, rewarding those who trusted the recommendation.

ALEC

Sell

Mar 07, 2025

Target

$1.50

Current

$2.14

Performance

48.61%

On Mar 07, 2025, Sean Laaman published a Underweight outlook on ALEC, with a target of 1.5. Investors who followed the Sell rating avoided losses as the stock weakened.

BGNE

Buy

Dec 03, 2024

Target

$300.00

Current

$184.71

Performance

-10.34%

Sean Laaman on Dec 03, 2024 assigned BGNE a Overweight rating, with a price target of 300. The call has struggled to gain traction, with shares losing 10.34%.

Frequency Asked Questions

Who is Sean Laaman?

Sean Laaman is an analyst from Morgan Stanley specializing in the Healthcare sector.

What is Sean Laaman's success rate?

Sean Laaman currently has a success rate of +75.12%.

How many ratings has Sean Laaman issued?

Sean Laaman has issued 29 stock ratings so far.

What is the average return of Sean Laaman's calls?

Their stock ratings have generated an average return of +13.76%.

What is Sean Laaman's ranking?

Sean Laaman is ranked #2297 out of 4773 analysts.

What types of ratings does Sean Laaman give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Sean Laaman?

You can follow Sean Laaman by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Sean Laaman?

Their latest rating was a Buy on ARGX issued on 2026-08-18.